Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Cancer|January 2, 2009
Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumorsLisa M McGregor, Sheri L Spunt, Victor M Santana, et al.
Journal of Pediatric Hematology/Oncology|March 18, 2014
Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastomaSara M Federico, Heather B Allewelt, Sheri L Spunt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecanClinton F Stewart, John C Panetta, Melinda A O'Shaughnessy, et al.
Pediatric Blood & Cancer|April 22, 2011
Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumorsLisa M McGregor, Clinton F Stewart, Kristine R Crews, et al.
Investigational New Drugs|July 29, 2011
A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastomaWayne L Furman, Lisa M McGregor, M Beth McCarville, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumorsWayne L Furman, Fariba Navid, Najat C Daw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2012
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumorsFariba Navid, Sharyn D Baker, M Beth McCarville, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2014
Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastomaFariba Navid, Paul M Sondel, Raymond Barfield, et al.
Pageof 3